Q4 2020 13F Holders as of 31 Dec 2020
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
71,366,920
-
Total 13F shares
-
22,245,476
-
Share change
-
+21,491,787
-
Total reported value
-
$728,255,975
-
Price per share
-
$33.13
-
Number of holders
-
73
-
Value change
-
+$703,285,064
-
Number of buys
-
68
Institutional Holders of C4 Therapeutics, Inc. - Common Stock, par value $0.0001 per share (CCCC) as of Q4 2020
As of 31 Dec 2020,
C4 Therapeutics, Inc. - Common Stock, par value $0.0001 per share (CCCC) was held by
73 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
22,245,476 shares.
The largest 10 holders included
PERCEPTIVE ADVISORS LLC, Cormorant Asset Management, LP, RTW INVESTMENTS, LP, Bain Capital Life Sciences Investors, LLC, PRICE T ROWE ASSOCIATES INC /MD/, RA CAPITAL MANAGEMENT, L.P., JANUS HENDERSON GROUP PLC, BlackRock Inc., ADAGE CAPITAL PARTNERS GP, L.L.C., and FMR LLC.
This page lists
73
institutional shareholders reporting positions in this security
for the Q4 2020 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.